Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Ibrutinib in High-Risk CLL
NCT02388048Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Oct 2015
- Primary completion
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by GIMEMA. Started Oct 2015; status: completed.
02
Drugs
ibrutinibofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02388048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388048.